Genzyme

3Q Revenues: $808.6 million (+14%)

3Q Earnings: $16 million (earnings were $115.7 million 3Q2005)*

YTD Revenues: $2.3 billion (+16%)

YTD Earnings: $251 million (-25%)

Comments: Myozyme was a significant new contributor in the quarter with the first full quarter of sales $20.4 million. Fabrazyme, Aldurazyme, Cerezyme and Renagel also contributed to revenue growth in the quarter. Sales of Fabrazyme rose 18% to $93.2 million. Sales of Aldurazyme rose 24% to $25 million. Sales of Cerezyme were $252.2 million, up 6%. Renagel sales were up 26% to $134.7 million in the quarter.

*Earnings for the quarter include a charge of $149.4 million for the impairment of goodwill associated with the company’s genetic testing business; an amortization expense of $31.9 million; and a stock compensation expense of $30.3 million.